Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows.
Recap: ChromaDex Q3 Earnings
ChromaDex (NASDAQ:CDXC) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:02 PM.
Here's what investors need to know about the announcement.
ChromaDex Q3 EPS $(0.13) Misses $(0.09) Estimate, Sales $17.31M Beat $17.17M Estimate
ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 85.71 percent decrease over losses of $(0.07) per share from the
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
ChromaDex Reports Jury In California Found Elysium Health Breached Its Contract With ChromaDex; Elysium, Mark Morris Will Pay Co. ~$2.25M-$2.5M In Damages, Estimated Interest
Elysium Health to pay ChromaDex approximately $2.25 to $2.50 million in damages plus interest for breach of contract
New partnership with Sinopharm Xingsha and recent partnerships with Walmart, H&H Group, and Ro to
ChromaDex Shares Preclinical Research Findings And Scientific Initiations From The ChromaDex External Research Program
ChromaDex Corp. (NASDAQ:CDXC) today announced findings from recently published preclinical studies, as well as recently registered clinical research, investigating Niagen® (patented nicotinamide riboside, or
Why Are ChromaDex Shares Trading Lower On Wednesday?
ChromaDex Corp (NASDAQ:CDXC) dropped over 20% during the premarket despite its announcement over plans to appeal a court ruling issued by…
ChromaDex Continues To Defend Strong Intellectual Property Portfolio And Plans To Appeal Judge’s Ruling In Patent Infringement Lawsuit
ChromaDex Corp. (NASDAQ:CDXC) issued the following statement:
ChromaDex announced today plans to appeal a September 14 decision granting a Motion for Summary Judgment (MSJ) in its lawsuit for patent infringement against